Co-Authors
This is a "connection" page, showing publications co-authored by CARLOS HERNANDO BARCENAS and RASHMI KRISHNA MURTHY.
Connection Strength
1.337
-
Reply to A. Pfob and C. Sidey-Gibbons. JCO Clin Cancer Inform. 2022 02; 6:e2100171.
Score: 0.208
-
Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform. 2021 08; 5:789-804.
Score: 0.201
-
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer. 2020; 6:11.
Score: 0.183
-
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
Score: 0.171
-
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist. 2019 03; 24(3):313-318.
Score: 0.164
-
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
Score: 0.162
-
Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2018 05; 16(5):518-524.
Score: 0.160
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.044
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
Score: 0.043